EDGAR Filing Documents for 0001062993-18-001130

Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]:

SEC Accession No. 0001062993-18-001130

Filing Date

2018-03-09

Accepted

2018-03-09 07:01:10

Documents

Period of Report

2017-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 40-F	form40f.htm	40-F	28836
2	EXHIBIT 99.1	exhibit99-1.htm	EX-99.1	319234
3	EXHIBIT 99.2	exhibit99-2.htm	EX-99.2	282458
4	EXHIBIT 99.3	exhibit99-3.htm	EX-99.3	434446
5	EXHIBIT 99.4	exhibit99-4.htm	EX-99.4	7118
6	EXHIBIT 99.5	exhibit99-5.htm	EX-99.5	7154
7	EXHIBIT 99.6	exhibit99-6.htm	EX-99.6	2529
8	EXHIBIT 99.7	exhibit99-7.htm	EX-99.7	2543
9	EXHIBIT 99.8	exhibit99-8.htm	EX-99.8	1514
10	GRAPHIC	exhibit99-1x1x1.jpg	GRAPHIC	6561
11	GRAPHIC	exhibit99-1x6x1.jpg	GRAPHIC	26196
12	GRAPHIC	exhibit99-1x8x1.jpg	GRAPHIC	32141
13	GRAPHIC	exhibit99-2x5x1.jpg	GRAPHIC	26012
14	GRAPHIC	exhibit99-2x6x1.jpg	GRAPHIC	32234
	Complete submission text file	0001062993-18-001130.txt		1257157

Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9

Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627

Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)